These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11361210)

  • 1. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center.
    Lindquist M; Edwards IR
    J Rheumatol; 2001 May; 28(5):1180-7. PubMed ID: 11361210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program.
    Singh G
    J Rheumatol; 2001 May; 28(5):1174-9. PubMed ID: 11361209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database.
    Letourneau M; Wells G; Walop W; Duclos P
    Vaccine; 2008 Feb; 26(9):1185-94. PubMed ID: 18243428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database.
    Ståhl M; Lindquist M; Edwards IR; Brown EG
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):355-63. PubMed ID: 15170764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacists' role in reporting adverse drug reactions in an international perspective.
    van Grootheest K; Olsson S; Couper M; de Jong-van den Berg L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):457-64. PubMed ID: 15269929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
    Du W; Levine M; Wang L; Zhang Y; Yi C; Wang H; Wang X; Xie H; Xu J; Jin H; Wang T; Huang G; Wu Y
    Can J Clin Pharmacol; 2007; 14(1):e40-4. PubMed ID: 17237524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European biologicals registers: methodology, selected results and perspectives.
    Zink A; Askling J; Dixon WG; Klareskog L; Silman AJ; Symmons DP
    Ann Rheum Dis; 2009 Aug; 68(8):1240-6. PubMed ID: 18647854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions and their measurement in the rheumatic diseases.
    Day RO; Quinn DI; Conaghan PG; Tett SE
    J Rheumatol; 1995 May; 22(5):983-8. PubMed ID: 8587095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reporting of fatal adverse drug reactions.
    Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
    Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Hill GR; Clark DW
    Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nurses are increasingly involved in pharmacovigilance in Sweden.
    Ulfvarson J; Mejyr S; Bergman U
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):532-7. PubMed ID: 17072915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How to cope with the global tuberculosis burden--experiences and perspectives for Japan's international cooperation].
    Ishikawa N
    Kekkaku; 2005 Feb; 80(2):89-94. PubMed ID: 15920981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
    Welch V; Singh G; Strand V; Fries J; Boers M; Ramey D; Day RO; Brooks P; Tugwell P; Clinch J; Kristjansson B
    J Rheumatol; 2001 May; 28(5):1188-91. PubMed ID: 11361211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of US poison centers in adverse drug reactions monitoring.
    Chyka PA
    Vet Hum Toxicol; 1999 Dec; 41(6):400-2. PubMed ID: 10592954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region].
    Biron P; Balency D
    Therapie; 1996; 51(5):578-81. PubMed ID: 9138400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis. OMERACT Drug Safety Working Party.
    Lipani JA; Strand V; Johnson K; Woodworth T; Furst D; Singh G; Day R; Brooks P;
    J Rheumatol; 2001 May; 28(5):1170-3. PubMed ID: 11361208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A proposal for a national program reporting beneficial drug responses, analogous to the existing program to detect adverse drug responses.
    Bond RA
    Med Hypotheses; 2006; 66(1):10-3. PubMed ID: 16198061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasally administered corticosteroids and neuropsychiatric disturbances: a review of the international pharmacovigilance programme of the World Health Organization.
    Pokladnikova J; Meyboom RH; Vlcek J; Edwards RI
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):67-73. PubMed ID: 18681087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.